PharmaIndustrial India Magazine September-October 2023

Shilpa Medicare Limited has received approval from the Office of the Direc - torate of Ayurveda and Unani Services (division of the Ministry of Aayush) for the manufacture and sale of Oral Mu- cositis Spray a treatment option made available for the first time in India under the brand name ORAAL ® . “The composition of ORAAL ® is pro- tected by a granted patent in India until November 2033.” Shilpa will commer- cialize the product under the brand name ORAAL® which will be launched immediately. ORAAL ® , a substantial advancement in Oral Mucositis management, has been accepted and approved by the Indian Dental Association (IDA). With the commitment towards ‘Thought- ful Innovation for Powerful Outcomes’, Shilpa’s ORAAL ® is indicated for the treatment of all grades of Mucositis. ORAAL ® is backed by required scien- tific proof for the treatment of Oral Mu - cositis. The launch of ORAAL ® , an Oral spray with a naturally derived formulation in India will offer great benefits in terms of flexibility and patient convenience for use in any condition, and is advanta- geous in reducing the chemical-based mouth rinse usage and also delivering appropriate dosing to the patient with- out any side effects. A dosage of 4-5 sprays, 2-3 times a day can maintain Oral hydration and work towards heal- ing Oral Mucositis from the first spray itself and starts showing effects within 20 minutes. Shilpa’s formula, enriched with Curcu - ma Longa, Honey, Glycerin, and Puri - fied Water, has been carefully crafted to provide soothing relief in a convenient spray form. Curcuma Longa: Nature’s Gift - Re - nowned for its anti-inflammatory prop - erties. Honey: Sweet Nectar - Known for its healing and antibacterial benefits. Glycerin & Purified Water: Hydration - Keeps mouth comfortable and moist. ORAAL ® forms a protective barrier, aid- ing in the healing process of oral mu- cositis. Say goodbye to discomfort and hello to relief! ORAAL ® is a ‘Sajeevani Muskurahat Ki’ for patients who are suf - fering from Oral Mucositis. Shilpa Medicare Limited is a re- search-driven, global, integrated phar- maceutical company, headquartered in Raichur, Karnataka, India, and is en - gaged in research and development, manufacturing, and sale of oncology drugs and formulations. Shilpa Medicare Launches Naturally Derived Option for the Treatment of Oral Mucositis under the Brand Name ORAAL™ PHARMA INDUSTRIALINDIA · SEP-OCT 23 27 PRODUCT